The activity of semuloparin and bemiparin was comparable in FXa-based assays

www.mynewsdesk.com/. /sanofi/. /data-at-asco-showcase-sanofi-s- commitment-to-research-and-identify-treatments-for-cancer-. CachedSanofi today announced that data from eight compounds in the company's robust

www.google.co.in/patents/WO2012055844A1?cl=zh-CNCachedThe invention relates to the use of semuloparin or a pharmaceutically .

www.mdedge.com/. /prophylactic-semuloparin-cuts-rate-vte-cancer-patientsFeb 15, 2012 . Prophylactic Semuloparin Cuts Rate of VTE in Cancer Patients . by

www.fiercepharma.com/. /research-and-markets-sanofi-aventis-pipeline- products-performance-potential-for-company-2010CachedDec 15, 2010 . Many of sanofi-aventis' products are facing patent expiry and declining sales. The

cdn2.hubspot.net/hub/. /adcomm_outcomes_summary_2013.pdfCachedApr 12, 2007 . Sanofi-Aventis. Zimulti (rimonabant) . N/A- Sanofi withdraws rimonabant NDA in

www.google.com.pg/patents/WO2011161235A1?cl=enCachedDec 29, 2011 . Semuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a new

www.thrombosisresearch.com/article/S0049-3848(11)00106-X/pdfApr 2, 2011 . molecular weight heparins such as semuloparin and bemiparin. Walter P. . b

https://www.biocentury.com/products/ave5026Cachedsanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product:

www.presseportal.de/nr/56778Aktuelle Pressemitteilungen im newsroom von sanofi-aventis Group. .

https://www.researchgate.net/. /0912f507c03f0be61d000000.pdfCachedcule otamixaban (sanofi-aventis) [12, 13]. . . Idrabiotaparinux (sanofi-aventis) is a

https://en.wikipedia.org/wiki/Semuloparin_sodiumCachedSimilarSemuloparin (INN, USAN) is an experimental antithrombotic being developed by

https://www.europeanpharmaceuticalreview.com/. /sanofi-aventis-withdraws- its-marketing-authorisation-application-for-mulsevo-semuloparin-so. CachedJul 9, 2012 . Sanofi-aventis withdraws its marketing authorisation application for . for the

https://www.clinicaltrialsregister.eu/ctr-search/rest/. /2007. /9270CachedMay 3, 2011 . Property of the sanofi-aventis group . Secondary: To evaluate the safety of

www.news.sanofi.us/press-releases?item=118557CachedJun 4, 2011 . Sanofi's Investigational Semuloparin in Cancer Patients Initiating Chemotherapy

www.google.mk/patents/US20130102566CachedSemuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a new

https://www.thestreet.com/. /sanofi-aventis-management-presents-at-credit- suisse-healthcare-conference-transcript.htmlCachedMar 16, 2012 . Page 3 of 3 - sanofi-aventis' Management Presents at Credit Suisse Healthcare .

https://www.google.co.in/patents/WO2012055843A1?cl=esCachedCachedThe invention relates to the use of semuloparin or a pharmaceutically .

www.ema.europa.eu/docs/en_GB/. /Press. /WC500129841.pdfCachedJul 9, 2012 . application for Mulsevo (semuloparin sodium). The European Medicines Agency

https://www.sciencedaily.com/releases/2010/07/100709083523.htmCachedJul 9, 2010 . An ultra-low-molecular-weight heparin called semuloparin has been found .

https://www.thepharmaletter.com/. /sanofi-presents-benefits-of-semuloparin- zaltrap-improves-colorectal-cancer-survivalCachedJun 7, 2011 . French drug major Sanofi (Euronext: SAN) announced results at the . Sanofi

en.sanofi.com/. trials. /clinical-study-results-pharma-letter-s.aspxCachedClinical Study Results - Sanofi Pharma, including Sanofi Genzyme. Information .

https://www.law360.com/. /fda-panel-won-t-back-sanofi-blood-thinner-for- cancer-patientsCachedJun 20, 2012 . . of a Sanofi Aventis US LLC anticoagulant for cancer patients receiving .

https://encrypted.google.com/patents/WO2012055844A1?cl=enMay 3, 2012 . Semuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a new

https://www.linkedin.com/title/assistant-international-managerPast, Assistant international manager Thrombosis/Oncology Semuloparin at

www.google.com.gt/patents/EP2399591A1?cl=enDec 28, 2011 . Semuloparin for the extended prevention of a mortality and/or . Semuloparin, or

adisinsight.springer.com/drugs/800022360Semuloparin, an indirect inhibitor of factor Xa and factor IIa, was in development

www.google.st/patents/EP2399593A1?cl=enCachedSemuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a new

https://www.medpagetoday.com/publichealthpolicy/. /33380CachedJun 20, 2012 . Drug manufacturer sanofi-aventis is seeking approval of semuloparin, an ultra-

ascopubs.org/doi/abs/10.1200/jco.2011.29.18_suppl.lba9014The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of

journals.lww.com/. /Preoperative_Enoxaparin_Versus_Postoperative.98115. aspxObjective: To compare efficacy and safety of thromboprophylaxis with

meetinglibrary.asco.org/content/101060-114CachedMethods: An ULMWH (semuloparin, Sanofi-aventis) and its high (HAF) and low (

www.bloodjournal.org/content/116/. /tab-e-letters%3Fsso-checked%3DtrueThe Ultra-Low-Molecular-Weight Heparin Semuloparin for Prevention of Venous

www.google.ch/patents/EP2399592A1?cl=enCachedSemuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a new

https://patentscope.wipo.int/search/en/detail.jsf?docId. (sanofi). Nov 15, 2012 . . anti-FIIa activity of about 2 U/mg, in particular semuloparin, for use as an

https://www.aaps.org/. /Sanofi-Aventis_Withdraws_Its_Marketing_ Authorisation_Application_for_Mulsevo_Semuloparin_Sodium/CachedSanofi-Aventis Withdraws Its Marketing Authorisation Application for Mulsevo

www.google.dj/patents/WO2012055844A1?cl=enCachedSemuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a new

https://www.healio.com/. /drug-study-shows-improvement-in-major- orthopedic-surgery-careJul 9, 2010 . Turpie is chairing the steering committee for the SAVE program, which is

https://encrypted.google.com/patents/WO2011161234A1?cl=fiThe invention relates to the use of semuloparin or a pharmaceutically acceptable

medcitynews.com/. /fda-panel-gives-thumbs-down-to-sanofi-bloodthinner- for-patients-on-chemo/CachedJun 20, 2012 . Semuloparin was designed to treat patients with certain cancers at higher .

www.thrombose-cancer.com/. /semuloparin-FDA-20.06.2012.pdfCachedOncologic Drugs Advisory Committee Meeting. June 20, 2012. NDA 203213.

https://www.clinicaltrials.gov/ct2/show/NCT00709904Sanofi. ClinicalTrials.gov Identifier: NCT00709904. First received: July 1, 2008.

https://www.fda.gov/AdvisoryCommittees/ucm302199.htmCached. will discuss New Drug Application (NDA) 203213, with the established name

https://pink.pharmamedtechbi.com/. /SanofiAventis-Semuloparin-May-Have -Safety-Advantage-For-ODAC-To-ConsiderSanofi-Aventis' Semuloparin May Have Safety Advantage For ODAC To Consider

https://www.google.com.na/patents/EP2399591A1?cl=enCachedDec 28, 2011 . Semuloparin, or AVE5026 (sanofi-aventis laboratory code) belongs to a .

https://encrypted.google.com/patents/WO2011161235A1?cl=fiThe invention relates to the use of semuloparin or a pharmaceutically acceptable

www.prnewswire.com/. /sanofis-investigational-semuloparin-in-cancer- patients-initiating-chemotherapy-shows-a-64-risk-reduction-in-life- . CachedSanofi's Investigational Semuloparin in Cancer Patients Initiating . Sanofi US,

www.medscape.com/viewarticle/766066CachedJun 20, 2012 . . reject the use of semuloparin sodium injection (sanofi-aventis) for the

www.advfn.com/nyse/StockNews.asp?stocknews=SNY&article. CachedJun 20, 2012 . Click Here for more Sanofi-Aventis Charts. By Jennifer Corbett Dooren.

www.ema.europa.eu/ema/index.jsp?curl=pages/news. CachedJul 9, 2012 . Sanofi-aventis withdraws its marketing authorisation application for . for the

Sitemap